OTC: AAVXF - ABIVAX Société Anonyme

Yield per half year: +0.9132%
Sector: Healthcare

Share chart ABIVAX Société Anonyme

Extended chart Simple chart
Financial Markets by TradingView

About

ABIVAX Société Anonyme, a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. The company is also developing obefazimod in Phase IIb/III pivotal planned studies for the treatment of Crohn's Disease; and completed Phase IIa clinical trials for the treatment of rheumatoid arthritis diseases.

More details
In addition, the company develops ABX 196, an immune enhancer candidate that is in Phase 1/2 POC clinical trial for the treatment of hepatocellular cancer, as well as a pre-clinical drug for the treatment of respiratory syncytial virus. It has license agreement with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Цена ао 11.05
Выручка 2.1E-5
EBITDA -0.0298
Число акций ао 0.04307 млрд
P/S 13388.54
P/BV 16.56
EV/EBITDA -9.58
Сайт https://www.abivax.com
Валюта usd
Sector Health Care
Industry Biotechnology
Валюта отчета eur
Change price per day: 0% (11.05)
Change price per week: 0% (11.05)
Change price per month: 0% (11.05)
Change price per 3 month: -27.06% (15.15)
Change price per half year: +0.9132% (10.95)
Change price per year: -10.16% (12.3)
Change price per 3 year: -72.17% (39.7)
Change price per 5 year: +51.99% (7.27)
Change price per year to date: -10.6% (12.36)
All parameters

Underestimation

Title Value Grade
P/S 86.25 1
P/BV 2.03 7
P/E 0 0
EV/EBITDA -1.54 0
Total: 4

Efficiency

Title Value Grade
ROA, % -45.17 0
ROE, % -75.37 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.4212 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 19991.3 10
Yield Ebitda, % 294.32 10
Yield EPS, % 15.22 3
Total: 8.6
More

Institutions Volume Share, %
iShares MSCI EAFE Small Cap ETF 72366 0.12
abrdn World Healthcare Fund 37000 0.06
College Retirement Equities Fund-Stock Account 26827 0.04
Fidelity SAI International Small Cap Index Fund 9418 0.01
SSgA SPDR ETFS Europe I-SPDR MSCI Europe Small Cap UCITS ETF 7659 0.01
State Street Inst Inv Tr-State St All Cap Glb Equity ex-US Index Port 3874 0.01
iShares MSCI Europe Small Cap ETF 3094 0
SSgA SPDR ETFS Europe I-SPDR MSCI Europe Small Cap Value Weighted 2172 0
SPDR (R) Portfolio Europe ETF 520 0
DBX ETF Trust-X-trackers MSCI Eurozone Hedged Equity 194 0



Head Job title Payment Year of birth
Dr. Philippe Pouletty M.D., Ph.D. Founder & Director N/A 1958 (66 years)
Mr. Marc M. P. de Garidel M.B.A. CEO & Director 850.26k 1958 (66 years)
Mr. Didier Blondel EVP, CFO & Board Secretary N/A 1964 (60 years)
Mr. Didier Scherrer Ph.D. Chief Scientific Officer N/A 1970 (54 years)
Mr. Patrick Malloy Senior Vice President of Investor Relations N/A
Ms. Ida Hatoum Chief People & Compliance Officer N/A 1975 (49 years)
Mr. Pierre Courteille M.B.A. Chief Business Officer N/A 1969 (55 years)
Mr. Michael Ferguson B.S., M.B.A. Chief Commercial Officer N/A 1978 (46 years)
Mr. Jerome Denis Ph.D. Executive Vice President of Process Development & Manufacturing N/A
Ms. Ana Sharma M.P.H. VP & Global Head of Quality

Address: France, Paris, 7-11 boulevard Haussmann - open in Google maps, open in Yandex maps
Website: https://www.abivax.com